Compare PSNYW & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSNYW | BNR |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Sweden | China |
| Employees | 2547 | N/A |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.4M | 233.6M |
| IPO Year | N/A | 2020 |
| Metric | PSNYW | BNR |
|---|---|---|
| Price | $7.09 | $20.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.4K | ★ 64.2K |
| Earning Date | 03-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,034,261,000.00 | $75,749,382.00 |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | $79.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $0.09 | $2.18 |
| 52 Week High | $0.61 | $24.18 |
| Indicator | PSNYW | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 79.76 | 56.81 |
| Support Level | $6.23 | $19.49 |
| Resistance Level | $7.50 | $21.57 |
| Average True Range (ATR) | 0.76 | 1.80 |
| MACD | 0.25 | -0.07 |
| Stochastic Oscillator | 86.22 | 58.32 |
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.